Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

A, Tefferi; J, Thiele; A, Orazi; HM, Kvasnicka; T, Barbui; CA, Hanson; G, Barosi; S, Verstovsek; G, Birgegard; R, Mesa; JT, Reilly; H, Gisslinger; AM, Vannucchi; F, Cervantes; G, Finazzi; R, Hoffman; DG, Gilliland; CD, Bloomfield; JW, Vardiman

doi:10.1182/blood-2007-04-083501

Public

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Shared by NobleBlocks on May 8, 2007 • 12:00 AM UTC

Authors:

Tefferi A

Thiele J

Orazi A

Abstract

The Janus kinase 2 mutation, JAK2617V>F, is myeloid neoplasm-specific; its presence excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other causes. Furthermore, JAK2617V>F or a JAK2 exon 12 mutation is present in virtually all patients with polycythemia vera (PV), whereas...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!